Paediatric anaesthesia & critical care

Bivalirudin use and Outcomes in Neonates With Congenital Diaphragmatic Hernia Managed With Extracorporeal Life Support

Ann SurgPublished Retrospective cohort study

Main finding · In-hospital mortalityResult — go to the resultAdjusted odds ratio 1.08 95% CI 0.42–2.82

Authors' conclusion

Among neonates with CDH supported with ECMO, bivalirudin use increased substantially over the study period and was associated with higher hospital charges but not with improved survival or reduced ECMO-related morbidity compared with unfractionated heparin.

Study context

Population
Neonates with congenital diaphragmatic hernia supported with extracorporeal membrane oxygenation (ECMO), 48 US children's hospitals, 2016–2023820 in final cohort
Participants
1,049 neonates
Exposure
Bivalirudin vs unfractionated heparin for ECMO anticoagulation
Outcome
In-hospital mortality
Methodological detailsmulticentre, multivariable logistic regression
  • Multicentre
  • Multivariable logistic regression

Main finding

As reported in the abstract

Adjusted odds ratio

1.08

95% CI 0.42–2.82

P = 0.87

Bivalirudin vs Heparin
aOR 1.08 (95% CI 0.42–2.82); P = 0.87
Overall in-hospital deaths in final cohort (48.5% mortality)
398

Observational data: associations, not effects.

Secondary outcomes

Median $

OutcomeBivalirudinHeparinP value
Hospital charges876,054 (IQR $652,735 - $1,366,728)577,326 (IQR $384,468 - $871,769)P < 0.0001

Bivalirudin utilization over time

Bivalirudin use in 2016
9.6%
Bivalirudin use in 2023
48.0%

Safety

OutcomeaOR (95% CI)P value
Bleeding1.43 (0.54–3.82)P = 0.47
Thrombosis1.88 (0.65–5.41)P = 0.24
Neurologic complications2.00 (0.81–4.91)P = 0.13

Original publication

Bivalirudin use and Outcomes in Neonates With Congenital Diaphragmatic Hernia Managed With Extracorporeal Life Support. Ann Surg. Published 22 June 2026. doi:10.1097/sla.0000000000007128

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.